Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS, Aoki M, Hayashi H, Hattori SI, Chang SB, Takamatsu Y, Martyr CD, Das D, Ghosh AK, Mitsuya H. Delino NS, et al. Among authors: mitsuya h. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02060-17. doi: 10.1128/AAC.02060-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463535 Free PMC article.
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Humphrey RW, Ohagen A, Davis DA, Fukazawa T, Hayashi H, Höglund S, Mitsuya H, Yarchoan R. Humphrey RW, et al. Among authors: mitsuya h. Antimicrob Agents Chemother. 1997 May;41(5):1017-23. doi: 10.1128/AAC.41.5.1017. Antimicrob Agents Chemother. 1997. PMID: 9145862 Free PMC article.
Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Mueller BU, Anderson BD, Farley MQ, Murphy R, Zuckerman J, Jarosinski P, Godwin K, McCully CL, Mitsuya H, Pizzo PA, Balis FM. Mueller BU, et al. Among authors: mitsuya h. Antimicrob Agents Chemother. 1998 Jul;42(7):1815-8. doi: 10.1128/AAC.42.7.1815. Antimicrob Agents Chemother. 1998. PMID: 9661027 Free PMC article. Clinical Trial.
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Humphrey RW, Wyvill KM, Nguyen BY, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, Yarchoan R. Humphrey RW, et al. Among authors: mitsuya h. Antiviral Res. 1999 Feb;41(1):21-33. doi: 10.1016/s0166-3542(98)00058-8. Antiviral Res. 1999. PMID: 10321576 Clinical Trial.
716 results